The Cancer/Tumor Profiling Market size was valued at USD 11.10 billion in 2021 and is
predicted to reach USD 31.67 billion by 2030 with a CAGR of 11.8% from 2022-2030. Cancer
profiling or the tumor profiling is a laboratory test conducted to identify certain genes or the
gene mutations, proteins, or other biomarkers in a sample of tumor tissue. Tumor profiling can
aid in treatment planning and predicting if cancer will return or spread to other places of the
body. Cancer profiling is not only effective in the molecular profiling of common malignancies
like lymphoma and breast cancer, but also in the molecular profiling of lung cancer, prostate
cancer, and acute leukaemia. Cancer profiling has become more important in molecular
diagnosis, since a better knowledge of cancer tumor allows clinicians to make more informed
therapeutic decisions and prevent "over-treating" cancer patients.
Market Segmentations and Scope of the Study:
The Cancer Tumor Profiling market is segmented on the basis of technique, technology,
application and geography. On the basis of technique, the market is divided into genomics,
proteomics, metabolomics, and epigenomics. On the basis of technology, the market is
classified into immunoassay, NGS, insitu hybridization, mass spectrometry, pcr, microarray
and others. On the basis of insitu hybridization, the market is further sub segmented into FISH
and CISH. On the basis of application, the market is categorized into research applications
and clinical applications. On the basis of research applications, the market is further sub
segmented into biomarker discovery and personalized cancer medicine. On the basis of
clinical application, the market is further classified into oncological diagnostics, prognostics,
monitoring and treatment, screening. Geographic breakdown and analysis of each of the
aforesaid segments includes regions comprising of North America, Europe, Asia-Pacific, and
RoW.
Request
before
buying-
https://www.nextmsc.com/Cancer-Tumor-Profiling-
Market/reque